Psoriatic Arthritis: Pharmacotherapy Update

Over the past decade, the assessment of the disease activity in psoriatic arthritis (PsA) has rapidly evolved in view of the need for valid, feasible, and reliable outcome measures that can be ideally employed in longitudinal cohorts, clinical trials, and clinical practice as well as the growing paradigm of tight disease control and treating to target in the management of PsA. This paper reviews the currently available measures used in the assessment of the disease activity in PsA. The composite measures for PsA that are under development are also discussed.

show abstract

“…It has been validated in assessment of psoriasis and shows discrimination and responsiveness in PsA trials [57–59]. …”

Section: Health-related Quality Of Lifementioning

confidence: 99%

Measuring Disease Activity in Psoriatic Arthritis

Wong

Leung

et al. 2012

International Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…Studies have shown that IL‐17 is involved in innate and adaptive immunity, and triggers and initiates inflammation . In recent years, many studies have found that IL‐17 is closely related with AS pathogenesis and many AS drugs for reducing IL‐17 have been developed …”

Section: Introductionmentioning

confidence: 99%

“…[5] In recent years, many studies have found that IL-17 is closely related with AS pathogenesis and many AS drugs for reducing have been developed. [6][7][8] Bilobalide (BIL) is a sesquiterpene compound extracted from the dried leaves of Ginkgo biloba. G biloba extract-761 (EEGb-761) is a combination of G biloba and other G biloba extracts.…”

Section: Introductionmentioning

confidence: 99%

Bilobalide alleviates IL‐17‐induced inflammatory injury in ATDC5 cells by downregulation of microRNA‐125a

Mao

Zhang

et al. 2019

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Ankylosing spondylitis (AS) is a high disability and greatly destructive disease. In this study, we preliminarily studied the function and mechanism of bilobalide (BIL) on interleukin (IL)‐17‐induced inflammatory injury in ATDC5 cells. CCK‐8 and migration assays were used to detect the functions of IL‐7, BIL, and microRNA (miR)‐125a on cell viability and migration. The miR‐125a level was changed by transfection, and tested by real‐time quantitative polymerase chain reaction. Additionally, Western blot tested the levels of inflammatory factors (IL‐6 and tumor necrosis factor‐α), matrix metalloproteinases (MMPs), and pathway‐related proteins. Moreover, the enzyme‐linked immunosorbent assay also was used to detect inflammatory factor levels. IL‐7 was used to construct an inflammatory injury model in ATDC5 cells. Based on this, BIL inhibited IL‐17‐induced cell viability, migration, and expressions of inflammatory factors and MMPs. Furthermore, we found BIL negatively regulated miR‐125a, and the miR‐125a mimic could partly reverse the effects of BIL on IL‐17‐injury. Finally, we showed that BIL inhibited the c‐Jun N‐terminal kinase (JNK) and nuclear factor kappa B (NF‐κB) pathways, and the miR‐125a mimic had the opposite effect. BIL inhibited IL‐17‐induced inflammatory injury in ATDC5 cells by downregulation of miR‐125a via JNK and NF‐κB signaling pathways.

show abstract

“…6 Small molecule inhibitors of RORc have also demonstrated efficacy in animal models. [7][8][9][10][11][12][13][14] Examples of recently reported RORc inverse agonists include TMP778 (1), GSK805 (2) and compound 3. 15, 16 We herein report the discovery of a series of novel pyrazole-containing benzamides as potent RORc inverse agonists (Fig.…”

Section: Introductionmentioning

confidence: 99%